Clinical and Immunologic Efficacy of the Recombinant Adenovirus Type-5-Vectored (CanSino Bio) Vaccine in University Professors during the COVID-19 Delta Wave

Guzmán-López, Santos; Darwich-Salazar, Armine; Bocanegra‐Ibarias, Paola; Salas-Treviño, Daniel; Flores-Treviño, Samantha; Pérez-Alba, Eduardo; Nuzzolo-Shihadeh, Laura; Pérez‐Rodríguez, Edelmiro; Camacho-Ortíz, Adrián

doi:10.3390/vaccines10050656

Cited by 8 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, these data can support a previous study in the Mexican population reporting that SARS-CoV-2 breakthrough infections during the Delta wave in a Mexican hospital mainly occurred in patients vaccinated with the Ad5-nCoV vaccine compared to those vaccinated with other platforms. Moreover, they suggested that a booster dose of the Ad5-nCoV vaccine is advisable for those individuals without previous infection to improve their immune response against SARS-CoV-2 [ 14 ].…”

Section: Discussionmentioning

confidence: 99%

Neutralizing antibody responses to the Delta variant of SARS-CoV-2 following vaccination with Ad5-nCoV (CanSino) in the Mexican population

Hernández-Bello,

Lorenzo-Leal,

Muñoz-Valle

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

During the COVID-19 pandemic, the Ad5-nCoV vaccine was applied to the Mexican population before the WHO approved it. In a transversal study, we compare the CanSino vaccine efficacy and a natural SARS-CoV-2 infection in eliciting neutralizing antibodies against the SARS-CoV-2 Delta variant in Guadalajara, Mexico. Participants between 30–60 years were included in the study and classified into three groups: 1) Natural immunity (unvaccinated), 2) Vaccine-induced immunity (vaccinated individuals without a COVID-19 history), and 3) Natural immunity + vaccine-induced immunity. These groups were matched by age and gender. We assessed the ability of individuals’ serum to neutralize the Delta variant and compared the results of the different groups using a neutralization test followed by plaque-forming units. Results showed that 39% of individuals’ serum with a history of COVID-19 (natural immunity, Group 1) could not neutralize the Delta variant, compared to 33% in vaccinated individuals without COVID-19 (vaccine immunity, Group 2). In contrast, only 7% of vaccinated individuals with a history of COVID-19 (natural + vaccine immunities) could not neutralize the Delta variant. We concluded that the effectiveness of the Ad5-nCoV vaccine to induce neutralizing antibodies against the Delta variant is comparable to that of natural infection (61% vs. 67%). However, in individuals with both forms of immunity (Group 3), it increased to 93%. Based on these results, despite the Ad5-nCoV vaccine originally being designed as a single-dose regimen, it could be recommended that even those who have recovered from COVID-19 should consider vaccination to boost their immunity against this variant.

show abstract

Section: Discussionmentioning

confidence: 99%

Neutralizing antibody responses to the Delta variant of SARS-CoV-2 following vaccination with Ad5-nCoV (CanSino) in the Mexican population

Hernández-Bello,

Lorenzo-Leal,

Muñoz-Valle

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Following this side effect of the administration of this vaccine, the FDA and CDC recommended stopping the administration of this vaccine [ 254 , 255 ]. Other vaccines which are used outside the US include AstraZeneca, Sputnik-V, and CanSino which are vector-based vaccines and an inactivated whole-virus SARS-CoV-2 vaccine (by Bharat Biotech and Sinovac) [ 256 , 257 ]. Here, we summarize the different types of COVID-19 vaccine candidates and clinical trials.…”

Section: Vaccine Developmentmentioning

confidence: 99%

COVID‐19: An Overview of SARS‐CoV‐2 Variants—The Current Vaccines and Drug Development

Bostanghadiri,

Ziaeefar,

Mofrad

et al. 2023

BioMed Research International

View full text Add to dashboard Cite

The world is presently in crisis facing an outbreak of a health-threatening microorganism known as COVID-19, responsible for causing uncommon viral pneumonia in humans. The virus was first reported in Wuhan, China, in early December 2019, and it quickly became a global concern due to the pandemic. Challenges in this regard have been compounded by the emergence of several variants such as B.1.1.7, B.1.351, P1, and B.1.617, which show an increase in transmission power and resistance to therapies and vaccines. Ongoing researches are focused on developing and manufacturing standard treatment strategies and effective vaccines to control the pandemic. Despite developing several vaccines such as Pfizer/BioNTech and Moderna approved by the U.S. Food and Drug Administration (FDA) and other vaccines in phase 4 clinical trials, preventive measures are mandatory to control the COVID-19 pandemic. In this review, based on the latest findings, we will discuss different types of drugs as therapeutic options and confirmed or developing vaccine candidates against SARS-CoV-2. We also discuss in detail the challenges posed by the variants and their effect on therapeutic and preventive interventions.

show abstract

“…Recombinant COVID-19 vaccine (adenovirus type 5 vector): Convidecia. Convidecia uses a third-generation novel coronavirus technology to produce humoral and cellular immunity (Zhu et al 2020a(Zhu et al , 2020b(Zhu et al , 2022bWu et al 2021;Halperin et al 2022;Richardson et al 2022;Guzmán-López et al 2022;. The vaccine can be stored between 2°C and 8°C.…”

Section: Covid-19 Vaccines (I)mentioning

confidence: 99%

The Race to Manufacture COVID-19 Vaccines: Emerging Vaccine Technologies

2023

View full text Add to dashboard Cite

Detailing how Australia’s Therapeutics Goods Administration conducted horizon scanning for new vaccines during the pandemic to assist ADB, this report is designed to help countries in Asia and the Pacific prepare for future outbreaks. It provides details of 16 vaccine manufacturers with novel and established vaccine technologies adapted to new pathogens like SARS-CoV-2, the virus that causes COVID-19. Offering information on their vaccine pipeline and partnerships, the report shows their approach to working with ADB’s developing member countries and can be used to inform decisions related to vaccine manufacturing and procurement.

show abstract

Clinical and Immunologic Efficacy of the Recombinant Adenovirus Type-5-Vectored (CanSino Bio) Vaccine in University Professors during the COVID-19 Delta Wave

Cited by 8 publications

References 15 publications

Neutralizing antibody responses to the Delta variant of SARS-CoV-2 following vaccination with Ad5-nCoV (CanSino) in the Mexican population

Neutralizing antibody responses to the Delta variant of SARS-CoV-2 following vaccination with Ad5-nCoV (CanSino) in the Mexican population

COVID‐19: An Overview of SARS‐CoV‐2 Variants—The Current Vaccines and Drug Development

The Race to Manufacture COVID-19 Vaccines: Emerging Vaccine Technologies

Contact Info

Product

Resources

About